In this meta-analysis, fourteen studies demonstrated the correction between GPRC5A expression and OS in human cancer pooled HRs with 95%CIs evaluated for OS was (1.69 95%CI 1.20–2.38 p = 0.05), using a random-effects model for high heterogeneity (I2 = 75.6% P< 0.001) (Fig 2). This evidence concerns the gene GPRC5A and cancer.